Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (57)

O. Sayar(1), L. Bueno(1), M.J. Garrido(1), F. Rombout(2), I.F. Trocóniz(1)

Comparison of different models to describe simultaneously the kinetics of parent drug and metabolites after oral administration.

F. Hourcade-Potelleret, C. Weber, B. Fotteler and N. Frey

Population PK Analysis in Sparse Data and Flexible Sampling Time Conditions

Emmanuelle Comets, France Mentré and François Gimenez

Cerebral uptake of mefloquine enantiomers with and without theP-gp inhibitor elacridar (GF1210918) in mice

K.C. Carlsson (1), N.O. Hoem (2), T. Glauser (3), A. A. Vinks (4).

Can clinically useful population PK models for carbamazepine in pediatric epilepsy patients be developed based on routine therapeutic drug monitoring (TDM) data?

Sandra A.G. Visser (1), Björn Sällström (1), Tomas Forsberg (2), Svante B. Ross (3), Lambertus A. Peletier (4) and Johan Gabrielsson (1)

Modeling of drug- and system-related changes in body temperature: application to drug-induced hypothermia, long-lasting tolerance development and diurnal variation in body temperature

E. Tousset (1), C. Reners (1) & B. Vrijens (1-2)

Identifying and minimizing major sources of variability in population pharmacokinetic studies

Isabelle Pouliquen, Lutz Harnisch

A Population PK/PD Model for Cortisol Suppression

K. Brendel (1), E. Comets (1), C. Laveille (2), R. Jochemsen (2), F. Mentré (1)

Comparison of several prediction errors on concentrations for model evaluation

Michael G Dodds(1), Andrew C. Hooker(1) and Paolo Vicini(1)

Robust Population Pharmacokinetic Experiment Design

Pieter Janssen(1,2), Nicolaas H. Prins(2), Pieter J. Peeters(2), Klaas P. Zuideveld(3) and Romain A. Lefebvre(1)

Quantification of 5-HT7 receptor efficacy distribution throughout the canine stomach using the operational model of agonism.

N.O. Hoem (1), P. Beringer (2)

A non-parametric (NPAG) population PK model of orally and intravenously administered linezolid.

Andrew Hooker, Michael G. Dodds, Paolo Vicini

Evaluating the predictive power of the Fisher information matrix in population optimal experimental design

Sylvie Retout, Emmanuelle Comets and France Mentré

Comparison between the Fedorov-Wynn algorithm and the Simplex algorithm for population designs optimisation using a model of the HIV viral load decrease

M Valle, M Yritia, R Antonijoan, G Urbano, MR Ballester, MJ Barbanoj

Population pharmacokinetic/pharmacodynamic modeling of the possible tolerance development after a single oral dose of different BZD-GABAa agonists.

Maria C. Kjellsson, Mats O. Karlsson

Fitting Proportional Odds model to Ordered Categorical Data using the NLMIXED Procedure

Michael G Dodds(1), Paolo Vicini(1), Jennifer E Visich(2) and Mark Rogge(2)

A Population PK Model for Recombinant Factor XIII in Congenitally Deficient Subjects

Niels Rode Kristensen

A Deconvolution Method for Linear and Nonlinear Systems based on Stochastic Differential Equations

Dymphy Huntjens (1), Anne Chain (1), David Spalding (2), Meindert Danhof (1) and Oscar Della Pasqua(1,3)

Population semi-parametric modelling of the pharmacokinetics of rofecoxib in rats

Poggesi I (1), Simeoni M (2), Germani M(1), De Nicolao G(2), Rocchetti M(1)

Population modeling of tumor growth in untreated xenografted mice

C Segura1, E Bandrés2, I F Trocóniz1, J García-Foncillas2,O Sayar1, C Dios-Vieitez1, M J Renedo1, M J Garrido1

Modelling of the effect of Topotecan on B cell subsets in tumor bearing rats.

Lars Lindbom, Pontus Pihlgren and E. Niclas Jonsson

PsN Toolkit, a collection of computer intensive methods for population PK/PD

Justin J Wilkins (1), Grant Langdon (1), Helen McIlleron (1), Goonaseelan Pillai (2), Peter J Smith (1) and Ulrika SH Simonsson (3)

A population pharmacokinetic-enzyme model for rifampicin autoinduction and bimodal absorption in pulmonary tuberculosis patients

CMJ Kirkpatrick(1), SB Duffull(1), ML Barclay(2), N Patton(3), GA Moore(4), MP Doogue( 1)

Population pharmacokinetic analysis of high-dose oral busulphan for bone marrow transplant in adults and children

Willi Weber, Diether Rueppel, Heiner Speth

Comparing efficacy of 10mg vs 20mg ARAVA in treatment of rheumatoid arthritis: A Population PK / PD Analysis

H. Silber (1), P. Stetina (1), B. McHugh (2), R. Gieschke (2), N. Frey (2), P. Vicini (3), U.S.H. Simonsson (1), M.O. Karlsson (1)

A disease model for the regulation of the glucose-insulin system

R. V. Overgaard(1,2), E. N. Jonsson(3), C. W. Tornøe(4), H. Madsen(2)

Non-Linear Mixed Effects Models with Stochastic Differential Equations – Implementation of an Estimation Algorithm

Marc Lavielle(1) and the Monolix research group(2)

SAEM in MATLAB: an alternative to linearization

C. Ambery (1), L. Aarons (1)

Population Pharmacokinetics and Response of ICL670 a Novel Oral Iron Chelator in Beta-Thalassaemia Patients

John C Lukas(1), Martina Samiotaki(2), Maria Kontou(2), Rosario Calvo(3), Panos Macheras(1), Tasos Zografidis(3), Georgios Kyriakides(4)

The cytochrome P450 3AP1 variant genotype shows correlation with the true clearance in a renal transplant population

K.H. Liesenfeld, EU. Gräfe-Mody, A. Staab, H.G. Schaefer

Population pharmacokinetics of a new anticoagulant drug in clinical development

S. Gisbert, L. Aarons and M. Rowland.

Different approaches to the development of a WBPBPK model with a series of barbiturates using population modelling

K. Ogungbenro, G. Graham and L. Aarons

The Design of Population Pharmacokinetic Studies: Sample Size Determination

T. Lehr (1), C. Tillmann (2), A. Staab (2), D. Trommeshauser (2), H.G. Schaefer (2), C. Kloft (1)

Clock time as a control variable for gall bladder emptying in an enterohepatic circulation model

E.Y.L. Blair(1), D.R. Mould(2), S.J. Clarke(3), L.P. Rivory(4), A.J. McLachlan(1)

Pharmacokinetic-Pharmacodynamic Modelling of Raltitrexed in Patients with Advanced Solid Tumours

Holger Kraiczi (1), Marianne Frisén (2)

Effect of Uncertainty About Population Parameters on Pharmacodynamics-Based Prediction of Clinical Trial Power – A Method for Sensitivity Analysis

B. Ploeger(2), N. Houwing(1), A. Bom(3), M.P. van Iersel(1), D. Zollinger(1), M. Danhof(2)

The reversal of rocuronium-induced neuromuscular block by the cyclodextrin ORG25969: model development and validation

Willem de Winter (1), Teun Post (1), Joost DeJongh (1,2), Richard Urquhardt(3), Ian Moules (3), David Eckland (3) and Meindert Danhof (1,2)

A Mechanistic Disease Progression Model for Type 2 Diabetes Mellitus and Pioglitazone Treatment Effects

Michael K. Smith(1), Scott Marshall(2), John Huggins(2).

A Bayesian design and analysis for dose-response using informative prior information

E Lamont (1), AH Thomson (2,3), M Dawber (2), L Semple (4), E Bell (4), RA Seaton (4)

Population Pharmacokinetics of Teicoplanin in Outpatient Home Parenteral Antibiotic Therapy (OHPAT)

Matthew L. Zierhut(1), Mark C. Peterson(2), Marc R. Gastonguay(3), Steven W. Martin(2), Paolo Vicini(1), Pirow J. Bekker(2), Donna Holloway(2), Philip T. Leese(4)

Development and Evaluation of a Population PK/PD Model for Fc-OPG in Healthy Postmenopausal Women

Aris Dokoumetzidis and Leon Aarons

Propagation of population pharmacokinetic information using a Bayesian approach

M. Pfister, S. Krishnaswami, S. Rohatagi

Characterization of Cortisol Circadian Rhythm and Lack of Cortisol Suppression by a New Corticosteroid, Ciclesonide

V. Piotrovsky(1), G. Kopia(2), G.W. Vetrovec(3), D. Rizik(4), David Snead(2)

Population pharmacokinetic analysis of concentration data after implantation of sirolimus-eluting Bx Velocity stent in patients

A.S. Zandvliet(1,2), A.D.R. Huitema(1,2), M.E. de Jonge(1,2), R. den Hoed(3), R.W. Sparidans(3), V.M. Hendriks(4,7), W. van den Brink(5,7), J.M. van Ree(6,7), J.H. Beijnen(1,2,3)

Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine

Jean-Eric Charoin(1), Philippe Jacqmin(2), Ludger Banken(3), Sian Lennon(4) and Karin Jorga(1)

Population Pharmacokinetic Analysis of Trastuzumab (Herceptin) following Long-Term Administration Using Different Regimens.

JS Barrett (1,4), A Zuppa (1,3), M Schreiner (5) and PC Adamson (1, 2, 4)

Esmolol Population Pharmacokinetics in Critically-ill, Pediatric Patients

Jakob Ribbing and E. Niclas Jonsson

Learning about Covariate Relations in the Patient Population Based on Data from Multiple Studies – Consequences of Different Approaches

L.E. Friberg, C. Dansirikul and S.B. Duffull

Simultaneous fit of competing models as a model discrimination tool in Bayesian analysis

Hugo Maas, Meindert Danhof, Oscar Della Pasqua

Comparison of sumatriptan and naratriptan using a markov model approach

F. Fiorentini (2), M. Simeoni (1), I. Poggesi (2), G. Westerberg (2), M. Rocchetti (2)

An example of application of the population approach to toxicological studies.

Annick Rousseau, Aurélie Prémaud, Pierre Marquet

Modeling the complex pharmacokinetic profiles of cyclosporin and of mycophenolate observed in the early post-transplantation period.

Vermeulen, An; Piotrovsky, Vladimir and De Ridder, Filip

Modeling the occurrence of orthostasis using a longitudinal logistic regression model

B. Mc Hugh, N. Frey

Population PK and PK/PD Analyses of an Enzyme Inhibitor in Healthy Volunteers

C. Lia Liefaard (1), Bart A. Ploeger (1,2), Carla F.M. Molthoff (3), Ronald Boellaard (3), Adriaan A. Lammertsma (3), Meindert Danhof (1,2), Rob A. Voskuyl (1,4)

Application of Population Pharmacokinetic Analysis for Quantification of in vivo Binding Properties in the Rat Brain by Positron Emission Tomography

Daniel M. Jonker (1), Derek Leishman (2), Rob Wallis (2), Peter E. Milligan (2) and E. Niclas Jonsson

Development and validation of a mechanism-based PK/PD model for the in vitro-in vivo prediction of QT prolongation by dofetilide

Simeoni M (1), Poggesi I (2), Germani M(2), De Nicolao G(1), Rocchetti M(2).

Population modeling of tumor growth inhibition in vivo: application to anticancer drug development

Xuejun Chen, Al Corey, Suresh Mallikaarjun, Steve Bramer

Population Pharmacodynamic Analysis of QTc Prolongation vs. Plasma Concentration